7月25日,丽珠医药与纽欧申医药联合宣布,高选择性小分子KCNQ2/3激活剂NS-041已完成Ⅱ期临床试验首例患者给药,标志着该创新药物正式进入临床疗效验证阶段。2024年7月,丽珠医药就纽欧申医药拥有全球知识产权的小分子候选药物NS-041达成一项大中华区独占许可协议,双方将在此基础上紧密合作开发,加速NS-041上市进程。NS-041是一款高选择性的KCNQ2/3激活剂,目标用于治疗癫痫和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.